IGC Pharma, Inc. IGC
0.28
0.00
0.00%
as of 25 Sep
- Market cap
- $29.1M
- P/E
- 0.0×
Follow IGC
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (143.46%) | (112.76%) | 0.00% | (83.35%) |
+8 more TTM periods Free account |
|
| (100.44%) | (78.30%) | 0.00% | (64.11%) | ||
ROIC |
(91.53%) | (79.70%) | 0.00% | (52.51%) | |
Return on Tangible Assets |
(7,422.03%) | (1,862.07%) | 0.00% | (241.91%) | |
Average Days of Receivables |
18.56 | 11.58 | 0.00 | 13.53 | |
Free Cash Flow per Share |
(0.06) | (0.04) | — | (0.05) | |
Free Cash Flow |
(5.69) | (4.08) | — | (4.83) | |
Capital Expenditures |
(0.35) | 0.64 | — | (0.02) | |
Piotroski F-Score |
1.00 | 3.00 | — | 3.00 | |
| Other line items | |||||
Cash ROIC |
(70.56%) | (64.90%) | 0.00% | (51.46%) | |
Accounts Receivable Turnover |
15.40 | 32.85 | 0.00 | 26.02 | |
Accounts Payable Turnover |
0.58 | 0.66 | 0.00 | 0.85 | |
Inventory Turnover |
0.75 | 0.70 | 0.00 | 0.55 | |
Average Days of Payables |
792.71 | 650.67 | 0.00 | 385.24 | |
Days of Inventory on Hand |
313.56 | 330.78 | 0.00 | 403.65 | |
Tax Rate |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
463.31% | 403.77% | — | 387.70% | |
Selling, General and Administrative Expense of Revenue |
481.47% | 379.85% | — | 390.42% | |
Share Based Compensation of Revenue |
225.52% | 187.91% | — | 141.32% | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Operating CF/Net income |
0.61 | 0.67 | — | 0.75 | |
Depreciation/Fixed assets |
0.11 | 0.15 | 0.00 | 0.19 | |
Capex/Depreciation |
(1.58) | 2.02 | — | (0.05) | |
Revenue per Share |
0.01 | 0.01 | — | 0.01 | |
Operating CF per Share |
(0.05) | (0.05) | — | (0.05) | |
Capex per Share |
0.00 | 0.01 | — | 0.00 | |
Capex to Sales |
0.32 | (0.55) | — | 0.02 | |
Net Profit Margin |
(795.46%) | (602.06%) | — | (582.91%) |
Columns are period end dates